Hangzhou MacroLink Biopharmaceutical

Hangzhou MacroLink Biopharmaceutical is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company utilizes its proprietary MlkCore technology platform to design ADCs with improved tumor penetration, site-specific conjugation, and enhanced stability to optimize efficacy and safety. Its lead candidate, MC002, is a first-in-class ADC targeting Sperm Autoantigenic Protein 17 (SPA17) and is currently being evaluated in Phase 1 clinical trials for advanced solid tumors, including esophageal and lung cancers. MacroLink aims to address unmet medical needs in oncology through innovative antibody designs and stable linker-payload combinations. The company's approach focuses on optimizing the Critical Quality Attributes (CQA) of ADCs to widen the therapeutic window and minimize off-target toxicity.